sk&f 104976 has been researched along with triparanol in 1 studies
*Triparanol: Antilipemic agent with high ophthalmic toxicity. According to Merck Index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts. [MeSH]
*Triparanol: Antilipemic agent with high ophthalmic toxicity. According to Merck Index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts. [MeSH]
| Studies (sk&f 104976) | Trials (sk&f 104976) | Recent Studies (post-2010) (sk&f 104976) | Studies (triparanol) | Trials (triparanol) | Recent Studies (post-2010) (triparanol) |
|---|---|---|---|---|---|
| 10 | 0 | 1 | 410 | 1 | 20 |
| Protein | Taxonomy | sk&f 104976 (IC50) | triparanol (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 7.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Busto, R; Cano, S; Dávalos, A; de la Peña, G; Giera, M; Herrera, E; Lasunción, MA; Sánchez-Wandelmer, J | 1 |
1 other study(ies) available for sk&f 104976 and triparanol
| Article | Year |
|---|---|
Inhibition of cholesterol biosynthesis disrupts lipid raft/caveolae and affects insulin receptor activation in 3T3-L1 preadipocytes.
Topics: 3T3-L1 Cells; Animals; Caveolae; Caveolin 1; Cell Membrane; Cholesterol; Dehydrocholesterols; Enzyme Inhibitors; G(M1) Ganglioside; Lanosterol; Membrane Microdomains; Mice; Receptor, Insulin; trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride; Triparanol | 2009 |